Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Hematopoietic Stem Cell Transplantation Using Bone Marrow Or Peripheral Blood Stem Cells From Matched, Unrelated, Volunteer Donors

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

PURPOSE: This phase II trial is studying how well giving chemotherapy with or without radiation therapy followed by donor stem cell transplant works in treating patients with hematologic cancer.

Study Overview

• Status: Completed
• Conditions: Lymphoma; Myelodysplastic Syndromes; Leukemia; Myelodysplastic/Myeloproliferative Diseases
• Intervention / Treatment: Drug: cyclophosphamide; Drug: cytarabine; Radiation: radiation therapy; Procedure: Stem Cell Transfusion; Drug: busulfan; Drug: Etoposide

Detailed Description

OBJECTIVES:

• Determine a standard approach to hematopoietic stem cell transplantation with matched unrelated donors in patients with hematologic malignancies.
• Determine the toxicity of this regimen in these patients.
• Determine the relapse rate and survival rate in patients treated with this regimen.
• Correlate incidence and severity of graft-versus-host disease with relapse and survival in patients treated with this regimen.

OUTLINE: Patients receive 1 of the following preparative regimens:

• Regimen A: Patients receive cytarabine IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1.
• Regimen B-1: Patients receive cyclophosphamide IV and TBI as in regimen A.
• Regimen B-2: Patients receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1.
• Regimen B-3: Patients receive TBI on days -7 to -5. Patients receive cyclophosphamide IV over on days -4 to -3.
• Regimen C: Patients receive oral busulfan 4 times daily on days -8 to -5 and cyclophosphamide IV over 2 hours on days -4 to -2.
• Regimen D: Patients receive TBI on days -6 to -4. Patients receive etoposide infusion on day -3.

All patients undergo stem cell transplantation from a matched, unrelated donor on day 0.

Patients are followed weekly for 100 days, at 6 months, and then every 6 months for 2.5 years.

PROJECTED ACCRUAL: 50

• Study Type: Interventional
• Enrollment (Actual): 34
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cleveland, Ohio, United States, 44106-5065
      • Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 55 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Eligibility Criteria:

1. Patients with histologic confirmation of the following diseases are eligible:

   1. AML in first, second or greater remission
   2. AML in early relapse, defined at <30% marrow blasts
   3. ALL in second or greater complete remission
   4. High risk ALL in first complete remission, with high risk being defined by the presence of t(4;11), t(9;22), or t(8;14) translocation, or patients presenting with extreme hyperleukocytosis (initial WBC >500 K/ml) or failure to achieve a complete remission after standard induction therapy.
   5. CML
   6. Myelodysplastic syndromes (including evolution to AML, e.g., Refractory Anemia with Excess Blasts (RAEB), or Refractory Anemia with Excess Blasts in transformation (RAEB-t).
   7. Lymphoma (intermediate and high grade) chemosensitive (CR or PR) after first or greater relapse or chemosensitive to first line therapy but only achieving PR.
   8. Hematologic Disease and Inherited Immunodeficiencies
   9. Hodgkin's disease, relapsed or refractory to standard treatments.
2. Patients must be less than or equal to 55 years of age.
3. Patients (or guardians if minor) must be able to give informed consent. Children older than 11 years of age must assent to the process.
4. Patients or their guardians must demonstrate proof-of-payment.
5. Patients must have an ECOG Performance Status of 2 or less. (See Appendix I)
6. Patients must have no evidence of active infection at the time of transplantation.
7. Patients must be HIV nonreactive.

8. Patients must have a pre-transplant, multi-organ assessment prior to transplantation with the following outcome:

   1. resting ejection fraction of 50% or greater (or shortening fraction greater than 28% for small children).
   2. Diffusion capacity of 50% or greater of predicted, a FEV1 of 50% or greater, and a P2O of 80 mm Hg as demonstrated on pulmonary function testing.
   3. serum creatinine of less than or equal to 2.0 mg/dL and/or a corrected creatinine clearance of 50 ml/min or greater on 24 hr urine.
   4. A total bilirubin of less than 2.5 mg/dL and an AST less than 4 times the upper limits of normal.
9. Females who are childbearing age may not be pregnant or lactating and must have a current negative pregnancy test

Ineligibility Criteria:

• Patients who have a life expectancy of less than three months with therapy.
• Patients who have an ECOG performance status greater than 2, (See Appendix I) or Lansky Scale < 70%.
• Patients who have angina and/or congestive heart failure requiring treatment, or who have had a myocardial infarction within the past year.
• Patients who have a resting ejection of less than 50% (or shortening fraction less than 28%) and who have not been cleared for transplant by cardiology
• Patients who have severe renal disease as demonstrated by a serum creatinine greater than 2.0 mg/dL and/or a corrected creatinine clearance less than 50 ml/min. (corrected for BSA of 1.73 m¬2)
• Patients who have had any complication that makes the risk of death during transplantation from non-malignant causes greater than the risk of relapse.
• Patients who have any active infection such as a soft tissue infection, sinus infection, dental infection, fungal infection or hepatitis including chronic active hepatitis; if the infection is successfully treated, the patient may be reconsidered for transplantation at a later date.
• Patients who have decreased pulmonary function due to any disorder as demonstrated by a diffusion capacity of less than 50% of predicted, a FEV1 of less than 50% of predicted or a PO2 of less than 80 mm Hg pulmonary function testing.
• Patients who have decreased liver function as demonstrated by a total bilirubin of greater than 2.5 mg/dL and/or an AST greater than 4 times the upper limits of normal.
• Patients who have diabetes mellitus will be considered on a case-by-case basis. However, patients with diabetes who are not controlled by medical management will be ineligible.

-Patients who have a significant psychiatric illness will be considered on a case- by-case basis. With the patient's consent, their Mental Health Care worker will assist the managing transplant physicians in determining if the patient can safely undergo transplantation and comply with followup recommendations.

• Psychosocial assessment by the bone marrow transplant team may identify individuals for whom this form of therapy may be contraindicated. This decision will be based upon estimated adequacy of patient support systems and prediction of patient's compliance with medications, required diagnostic procedures and/or follow-up care.
• Females who are childbearing age may not be pregnant or lactating and must have a current negative pregnancy test
• Patients who had a stem cell transplant less than one year earlier

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Regimen A; Patients receive cytarabine 3.0gm/M² IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI), 165 cGY, twice daily on days -4 to -1 for a total of 1320 cGY.	Drug: cyclophosphamide; Given IV; Other Names: CPM; CTX; cytoxan; Drug: cytarabine; Given IV; Other Names: Ara-C; Cytosar-U; Cytosine Arabinoside; Arabinosyl; Radiation: radiation therapy; Patients undergo total body irradiation; Other Names: Total body irradiation; Procedure: Stem Cell Transfusion
Experimental: Regimen B-1; Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..	Drug: cyclophosphamide; Given IV; Other Names: CPM; CTX; cytoxan; Radiation: radiation therapy; Patients undergo total body irradiation; Other Names: Total body irradiation; Procedure: Stem Cell Transfusion
Experimental: Regimen B-2; Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.	Drug: cyclophosphamide; Given IV; Other Names: CPM; CTX; cytoxan; Radiation: radiation therapy; Patients undergo total body irradiation; Other Names: Total body irradiation; Procedure: Stem Cell Transfusion
Experimental: Regimen C; Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.	Drug: cyclophosphamide; Given IV; Other Names: CPM; CTX; cytoxan; Procedure: Stem Cell Transfusion; Drug: busulfan; Given orally 1mg/kg/dose (or 40mg/m2/dose for young children); Other Names: Myleran
Experimental: Regimen B-3; Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.	Drug: cyclophosphamide; Given IV; Other Names: CPM; CTX; cytoxan; Radiation: radiation therapy; Patients undergo total body irradiation; Other Names: Total body irradiation; Procedure: Stem Cell Transfusion
Experimental: Regimen D; Patients receive total body irradiation (TBI) on days T -6, -5 and -4 for a total of 1320 cGy , then etoposide (60mg/kg/dose) on day -3.	Radiation: radiation therapy; Patients undergo total body irradiation; Other Names: Total body irradiation; Procedure: Stem Cell Transfusion; Drug: Etoposide; infusion; Other Names: EPEG; VP-16; VP-16-213; VePesid®; epipodophyllotoixn

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rates of Durable Engraftment	Number of days that patients take to reach engraftment defined as time to hematologic engraftment will be defined as ANC >500/µl and platelets >20K/µl without transfusion support.	at day 42

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Graft-versus-host Disease (GVHD)	Number of patients that develop acute graft-versus-host disease by grades 0-4. Grade O is no development of GVHD. Grade 1-4 is increase severity of skin, liver and gut involvement with 1 being least severe and 4 being most severe.	at 100 days post transplant
Incidence of Recurrent Disease	Number of patients that have disease recurrence.	at day 100 post transplant
Toxicity as Measured by CTC v2.0	Number of patients that experience grade 3 or above toxicity. See serious adverse event list for toxicities.	at 100 days post transplant

Collaborators and Investigators

• Sponsor: Case Comprehensive Cancer Center
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Kenneth Cooke, MD, Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Study record dates

Study Major Dates

• Study Start: November 1, 2000
• Primary Completion (Actual): September 1, 2011
• Study Completion (Actual): September 1, 2011

Study Registration Dates

• First Submitted: February 5, 2003
• First Submitted That Met QC Criteria: February 5, 2003
• First Posted (Estimate): February 6, 2003

Study Record Updates

• Last Update Posted (Estimate): July 24, 2013
• Last Update Submitted That Met QC Criteria: June 19, 2013
• Last Verified: June 1, 2013

More Information

Terms related to this study

• Keywords: recurrent grade 3 follicular lymphoma; recurrent adult diffuse large cell lymphoma; recurrent adult immunoblastic large cell lymphoma; recurrent adult Burkitt lymphoma; recurrent childhood small noncleaved cell lymphoma; recurrent childhood large cell lymphoma; refractory anemia; refractory anemia with ringed sideroblasts; refractory anemia with excess blasts; refractory anemia with excess blasts in transformation; chronic myelomonocytic leukemia; de novo myelodysplastic syndromes; previously treated myelodysplastic syndromes; secondary myelodysplastic syndromes; adult acute myeloid leukemia with 11q23 (MLL) abnormalities; adult acute myeloid leukemia with inv(16)(p13;q22); adult acute myeloid leukemia with t(15;17)(q22;q12); adult acute myeloid leukemia with t(16;16)(p13;q22); adult acute myeloid leukemia with t(8;21)(q22;q22); secondary acute myeloid leukemia; childhood acute lymphoblastic leukemia in remission; childhood acute myeloid leukemia in remission; juvenile myelomonocytic leukemia; chronic phase chronic myelogenous leukemia; childhood chronic myelogenous leukemia; childhood myelodysplastic syndromes; recurrent adult acute myeloid leukemia; atypical chronic myeloid leukemia; myelodysplastic/myeloproliferative disease, unclassifiable; adult acute myeloid leukemia in remission; recurrent adult diffuse small cleaved cell lymphoma; recurrent adult diffuse mixed cell lymphoma; blastic phase chronic myelogenous leukemia; relapsing chronic myelogenous leukemia; recurrent adult lymphoblastic lymphoma; recurrent mantle cell lymphoma; accelerated phase chronic myelogenous leukemia; adult acute lymphoblastic leukemia in remission; recurrent childhood acute myeloid leukemia; recurrent childhood lymphoblastic lymphoma; refractory cytopenia with multilineage dysplasia
• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Disease; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Lymphoma; Syndrome; Myelodysplastic Syndromes; Leukemia; Preleukemia; Myeloproliferative Disorders; Myelodysplastic-Myeloproliferative Diseases; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Cyclophosphamide; Etoposide; Etoposide phosphate; Cytarabine; Busulfan
• Other Study ID Numbers: CWRU1Y00; P30CA043703 (U.S. NIH Grant/Contract); CASE-CWRU-1Y00 (Other Identifier: Case Comprehensive Cancer Center)